TAP-I Deficiency Presenting With Chronic Granulomatous Rubella Virus-Driven Cutaneous Ulceration: A Case Report and Scoping Literature Review
Mark Ponsford(University Hospital of Wales), Manju Kalavala(University College London Hospitals NHS Foundation Trust), Stephen Jolles(University Hospital of Wales), Kathleen E. Sullivan(Children's Hospital of Philadelphia), Angharad N. Williams(Max Planck Institute for Human Cognitive and Brain Sciences), Jennifer M. Gardner(Seattle Cancer Care Alliance), Ian Tully(University Hospital of Wales), Emily Carne(University Hospital of Wales), Zoë Morrison(Cardiff University), Jennifer Evans(University Hospital of Wales), Simon Kollnberger(Nuffield Orthopaedic Centre), Kathryn Bramhall(Centers for Disease Control and Prevention), Kristin Ladell(Cardiff University), Sian Llewellyn‐Lacey(University College London Hospitals NHS Foundation Trust), Ludmila Perelygina(Centers for Disease Control and Prevention), Martin P. Edwards(Pfizer (United States)), Venetia Bigley(National Health Service), Kelly L. Miners(University Hospital of Wales), Daniel Farewell(Cardiff University), Aung Saw(University Hospital of Wales), David A. Price(University Hospital of Wales), Siân Hughes(University College London Hospitals NHS Foundation Trust), Flora Joseph(University Hospital of Wales), Matthew Spencer(University Hospital of Wales), Sian Williams, Stephen L. Walker(University College London Hospitals NHS Foundation Trust), Beth McIldowie(Cardiff University)
Cited by 2
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924